Webinar: Beyond US Borders - What do global drug prices really mean for MFN?
In collaboration with Jayson Slotnik, Health Policy Strategies, Inc.
In collaboration with Jayson Slotnik, Health Policy Strategies, Inc.
The U.S. government is increasingly looking to benchmark drug prices against those in international markets, where prices are typically lower. This shift is highly relevant for U.S. biotech companies with global ambitions or those preparing for launch.
In this session, we have demystified how drug pricing works outside the United States. We have explained key ex-U.S. pricing mechanisms and discussed why they matter in the context of the Most Favored Nation (MFN) Policy.
Together with Jayson Slotnik, we have also assessed the practical implications of MFN:
- How likely is it to be implemented?
- What types of ex-U.S. price data could be referenced?
- And most importantly, what does this mean for your pricing strategy and evidence requirements?
This session has been tailored for U.S.-based biotech executives, policy teams, access and commercial leaders looking to better understand the global pricing landscape and its strategic implications under MFN.
The webinar took place June 30th, 9am PT | 12pm ET.
You can find the entire slide deck (pdf) here:
Webinar: Beyond US Borders - What do global drug prices really mean for MFN?